Mar 22, 2024, 23:26
Bishal Gyawali: The totality of evidence remains against routine adoption of adjuvant cdk4/6 as the default SOC
Bishal Gyawali, Associate Professor and Medical Oncologist at
“This is a really good summary. Plus informative censoring and other adjuvant Cdk 4/6 trials with equally dubious results. The totality of evidence remains against routine adoption of adjuvant cdk4/6 as the default SOC. We discussed this in detail in our The Lancet Oncology essay, which still remains valid.”
Quoting Mark Bolton’s post:
“NATALEE: A good example of clinically insignificant ~3% benefit in a contrived endpoint at 3-years that jacks up toxicity, plus what happens at ~40 months? Hard to tell without CIs.”
Source: Bishal Gyawali/X and Mark Bolton/X